Cardiology

Sarcoma

Questions discussed in this category

Would you give doxorubicin and cisplatin for localized chondroblastic osteosarcoma in a patient with prior childhood anthracycline exposure and resultant cardiomyopathy with EF 50%?

3 Answers available

For a patient with cardiac sarcoma, is there a minimum ejection fraction to proceed with adjuvant radiation therapy?

1 Answer available

What therapy would you recommend for metastatic myxoid liposarcoma in a young patient with anthracycline cardiomyopathy with EF 25% who failed eribulin?

Would you even consider trabectedin in this case given its cardiotoxicity?

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997-06

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

Clin Cancer Res, 2021 Mar 25

Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.

The American journal of cardiology, 2018-12-01

Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.

Curr Oncol, 2021 Oct 13

Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors.

Cardiooncology, 2019 Jan 29

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.

Related Topics in Cardiology